TY - JOUR
T1 - Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors
AU - Koshiba, Takatomo
AU - Hosotani, Ryo
AU - Miyamoto, Yoshiharu
AU - Wada, Michihiko
AU - Lee, Jeon Uk
AU - Fujimoto, Koji
AU - Tsuji, Shoichiro
AU - Nakajima, Sanae
AU - Doi, Ryuichiro
AU - Imamura, Masayuki
N1 - Funding Information:
This study was supported in part by a grant from the Ministry of Education of Japan. Part of this study was presentated in the 8th meeting of the International Association of Pancreatology.
PY - 1999
Y1 - 1999
N2 - Background. A considerable amount of evidence collected from several experimental systems and clinical studies with nonsteroidal Anti-inflammatory drugs (NSAIDs) indicates that Cox-2 may play a major role in colorectal tumorigenesis, but little information about Cox-2 expression in pancreatic tumors is available. In this study, we investigated Cox-2 expression by means of both immunohistochemical analysis and immunoblot analysis in pancreatic tumors. Methods. Fifty invasive ductal adenocarcinomas and 26 intraductal papillary-mucinous tumors (IPMTs) were used for immunohistochemical analysis, and five pancreatic cancer tissues and five pancreatic cancer cell lines for immunoblot analysis. Results. Cox-2 was expressed in 72% of the invasive ductal adenocarcinomas, 31% of intraductal papillary-mucinous adenocarcinomas, and none of intraductal papillary-mucinous adenomas. The expression rate of Cox-2 in intraductal papillary-mucinous adenocarcinomas was significantly higher than that in intraductal papillary-mucinous adenomas, and that in invasive ductal adenocarcinomas was significantly higher than that in intraductal papillary-mucinous carcinomas. However, there was no significant correlation between Cox-2 expression and the prognosis and clinicopathological factors. Immunoblot analysis identified Cox-2 in all of pancreatic cancer tissues and 60% of cell lines. Conclusion. The biological role of cyclooxygenase-2 (Cox-2) in carcinoma cells should be investigated with reference to the cancer progression of the pancreas.
AB - Background. A considerable amount of evidence collected from several experimental systems and clinical studies with nonsteroidal Anti-inflammatory drugs (NSAIDs) indicates that Cox-2 may play a major role in colorectal tumorigenesis, but little information about Cox-2 expression in pancreatic tumors is available. In this study, we investigated Cox-2 expression by means of both immunohistochemical analysis and immunoblot analysis in pancreatic tumors. Methods. Fifty invasive ductal adenocarcinomas and 26 intraductal papillary-mucinous tumors (IPMTs) were used for immunohistochemical analysis, and five pancreatic cancer tissues and five pancreatic cancer cell lines for immunoblot analysis. Results. Cox-2 was expressed in 72% of the invasive ductal adenocarcinomas, 31% of intraductal papillary-mucinous adenocarcinomas, and none of intraductal papillary-mucinous adenomas. The expression rate of Cox-2 in intraductal papillary-mucinous adenocarcinomas was significantly higher than that in intraductal papillary-mucinous adenomas, and that in invasive ductal adenocarcinomas was significantly higher than that in intraductal papillary-mucinous carcinomas. However, there was no significant correlation between Cox-2 expression and the prognosis and clinicopathological factors. Immunoblot analysis identified Cox-2 in all of pancreatic cancer tissues and 60% of cell lines. Conclusion. The biological role of cyclooxygenase-2 (Cox-2) in carcinoma cells should be investigated with reference to the cancer progression of the pancreas.
UR - https://www.scopus.com/pages/publications/0032704323
UR - https://www.scopus.com/pages/publications/0032704323#tab=citedBy
U2 - 10.1007/bf02781733
DO - 10.1007/bf02781733
M3 - Article
C2 - 10597402
AN - SCOPUS:0032704323
SN - 0169-4197
VL - 26
SP - 69
EP - 76
JO - International Journal of Pancreatology
JF - International Journal of Pancreatology
IS - 2
ER -
